Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ATTAIN Clear all
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 15, 2026, 5:34 AM EDT
Completed No phase listed Observational

Model 4196 Left Ventricular (LV) Lead Chronic Performance Study

NCT00930904
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
1,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Sep 15, 2026, 5:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

NCT00311987
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
3,5-Diiodothyropropionic acid (DITPA) therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

NCT00789828
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 15, 2026, 5:34 AM EDT
Not yet recruiting Not applicable Interventional

Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

NCT05921149
View directory record Official record
Conditions
Ovarian Cancer, Chemotherapeutic Toxicity
Interventions
Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet
Dietary Supplement · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT00251004
View directory record Official record
Conditions
Kidney Transplantation, Graft Rejection
Interventions
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Sequential Multiple Assignment Treatment for Bipolar Disorder

NCT01588457
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
Lithium, Divalproex, Lamotrigine, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 15, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

NCT00115739
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 15, 2026, 5:34 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Show Rates in Dental Care Settings Serving Underserved Populations

NCT06581250
View directory record Official record
Conditions
Dental Care
Interventions
Reminder Messages, Walk-in Visits, Motivation-enhanced Communication
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure

NCT00223678
View directory record Official record
Conditions
Kidney Transplant
Interventions
Rapamycin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 15, 2026, 5:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Access to Tailored Autism Integrated Care Pilot Study

NCT04293627
View directory record Official record
Conditions
Autism Spectrum Disorder, Mental Health Issue
Interventions
ATTAIN
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Effect of Testosterone in Men With Erectile Dysfunction

NCT00512707
View directory record Official record
Conditions
Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions
Sildenafil citrate (open label), Testosterone gel, Placebo gel
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Not applicable Interventional

eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS

NCT03829267
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
eFIT Intervention, eJournal Intervention, Treatment as usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 15, 2026, 5:34 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06763341
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery

NCT02071251
View directory record Official record
Conditions
Wound Complications, Wound Infection, Wound Separation
Interventions
Prospective wound complication protocol
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 15, 2026, 5:34 AM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

NCT04774822
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
Procedure · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 15, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422
View directory record Official record
Conditions
Hypertension
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Covina, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Attain Performa(TM) Quadripolar Lead Study

NCT01751022
View directory record Official record
Conditions
Heart Failure
Interventions
Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Glendale, California • Riverside, California • San Diego, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods

NCT00235807
View directory record Official record
Conditions
Tinnitus
Interventions
Tinnitus Masking, Tinnitus Retraining Therapy (TRT), Tinnitus Education (TED)
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Sep 15, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530
View directory record Official record
Conditions
Hypertension
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Phoenix, Arizona • Covina, California • Northridge, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Not applicable Interventional

VIDA Mobile Health Cardiovascular Prevention Program

NCT02431546
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Mobile Health Application
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 15, 2026, 5:34 AM EDT
Active, not recruiting No phase listed Observational

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

NCT04489225
View directory record Official record
Conditions
Heart Failure
Interventions
Observational
Other
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 15, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Active for Life: Chronic Obstructive Pulmonary Disease

NCT03201198
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Active Life, Chair exercises
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 15, 2026, 5:34 AM EDT